BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 47 found
  Current Search:  calcitonin: 47, salmon: 80     

HTML
100%
Focusing on Task of Reinventing Peptide Drugs
Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.

Levy, Ph.D.

Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...

Genetic Engineering News:  Jul 3 2008 4:39PM
Matching: calcitonin salmon
Find similar documents
HTML
100%
Premium Company Profile Nastech Pharmaceutical - New Research Report on Companies and Markets
Company-Profile/Premium-Comp ..

Introduction Nastechs goal is to become a leader in both the development and commercialization of innovative, nasal drug delivery products and technologies, as well as in RNAi therapeutics.

Scope Contains...

PR inside:  Jul 2 2008 1:01PM
Matching: calcitonin salmon
Find similar documents
HTML
100%
Focusing on Task of Reinventing Peptide Drugs
Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.

Levy, Ph.D.

Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...

Genetic Engineering News:  Jul 1 2008 10:05PM
Matching: calcitonin salmon
Find similar documents
HTML
52%
Experimental Agent Significantly Improves Migraine Pain, Symptoms
June 30, 2008 (Boston, Massachusetts) An investigational oral migraine medication is effective in the treatment of acute moderate to severe attacks and associated symptoms without the direct vasoconstrictive effects typically associated with...
Medscape:  Jun 30 2008 7:09PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
- Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...

DiGiTAL50:  Jun 28 2008 9:15AM
Matching: calcitonin
Find similar documents
HTML
52%
Merck Stretching to New Day Highs on Migraine Treatment Study
(MidnightTrader via COMTEX News Network) -- Merck (MRK) is soaring to new highs heading into the last hour of regular session trade, up 4.5% at 37.82, near its new day high of 37.88.

The company announced earlier today that, in a Phase III...

Macro World Investor:  Jun 27 2008 7:53PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck Stretching to New Day Highs on Migraine Treatment Study
(MidnightTrader via COMTEX News Network) -- Merck (MRK) is soaring to new highs heading into the last hour of regular session trade, up 4.5% at 37.82, near its new day high of 37.88.

The company announced earlier today that, in a Phase III...

Calibre Macro World:  Jun 27 2008 7:22PM
Matching: calcitonin
Find similar documents
HTML
52%
::: Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in P
Oral CGRP Receptor Antagonist Provided Similar Migraine Relief with Fewer Adverse Events Compared to Zolmitriptan BOSTON--(BUSINESS WIRE)--Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK...

Biotech Intelligence:  Jun 27 2008 6:04PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's (MRK) Investigational Migraine Treatment Improved Pain and Associated Symptoms in Phase III Study
Merck (NYSE: MRK) announced that in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and...
Street Insider:  Jun 27 2008 5:37PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
- Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...

Therapeutics Daily:  Jun 27 2008 4:46PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
- Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...

Pharma Live:  Jun 27 2008 4:16PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain, Migraine-Associated Symptoms in Phase II
(RTTNews) - Merck & Co.

(MRK: News, Chart, Quote ) said that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide receptor antagonist, significantly improved...

RTTNews.com:  Jun 27 2008 3:48PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
Merck&Co., (News/Aktienkurs) Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved...

FinanzNachrichten.de:  Jun 27 2008 3:33PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
BOSTON--(BUSINESS WIRE)-- Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly...

Street Insider:  Jun 27 2008 3:25PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
BOSTON--(BUSINESS WIRE)--Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly...

Yahoo! Canada:  Jun 27 2008 3:22PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase
Author : MA-MERCK/TELCAGEPANT Category : Press Release News Alerts by Email ( click here ) Press Release News | Home BOSTON - (Business Wire) Merck & Co., Inc.

today announced that, in a Phase III clinical trial, telcagepant ...

Earthtimes.org:  Jun 27 2008 3:12PM
Matching: calcitonin
Find similar documents
HTML
52%
Merck Migraine Drug Comparable To AstraZeneca Drug In Study
An experimental drug from Results of the Phase 3, or late-stage, trial were summarized in an abstract posted on the website of the American Headache Society.

Full results will be presented at the society's annual meeting in Boston MK-0974...

Morningstar.com:  Jun 23 2008 10:42PM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
- A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
DiGiTAL50:  Jun 20 2008 7:02AM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
- A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
Pharma Live:  Jun 19 2008 10:35PM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
PENZBERG, Germany - (Business Wire) A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin...
Earthtimes.org:  Jun 19 2008 11:28AM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.

These...

Forbes.com:  Jun 19 2008 11:27AM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
PENZBERG, Germany--(BUSINESS WIRE)--A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin...
Yahoo! Canada:  Jun 19 2008 11:21AM
Matching: calcitonin
Find similar documents
HTML
52%
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells
-A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
Calibre Macro World:  Jun 19 2008 11:05AM
Matching: calcitonin
Find similar documents
HTML
52%
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall/ -- Exelixis, Inc.

announced today that the company and the U.S.

Food and Drug Administration (FDA...

Pharma Live:  Jun 18 2008 4:34AM
Matching: calcitonin
Find similar documents
HTML
52%
Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer
PM South San Francisco-based Exelixis Inc.

reached an agreement with the FDA for a special protocol assessment for its pivotal Phase III trial of XL184, a small-molecule compound targeting MET, RET and VEGFR2, in medullary thyroid cancer....

Macro World Investor:  Jun 17 2008 2:25AM
Matching: calcitonin
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.